Immedica Pharma AB (Immedica) has acquired rights to four ophthalmology products involving indications for the treatment of glaucoma, allergic conjunctivitis, and inflammatory conditions of the eye, in certain European countries from Novartis. The deal encompasses commercial and distribution rights and intellectual property for the four products in the territories.
All four products are since long part of standard pharmaceutical treatments in their respective indications and territories, and the products constitute valuable and reliable treatment options for numerous patients in this specialty care field.
“We are truly happy being able to offer these products to many patients also in the future.” says Anders Edvell, CEO of Immedica.
During an initial transition period Immedica will collaborate with Novartis for the commercial operations of the products. Immedica will thereafter start direct distribution and sales operations in its territory.
“These four ophthalmology products will be important in the growth of Immedica as well as in our continued commitment towards specialty care patients and care-givers, primarily in Europe,” concludes Anders Edvell.
About Immedica Pharma AB
Immedica is a fast-growing private niche specialty pharma group, with the headquarter based in Stockholm, Sweden, and the company has commercial coverage across Europe and the Middle East.
Immedica provides significant know-how and experience from commercialization of niche/specialty care products across Europe and the Middle East, and the company’s management team has an outstanding track record of transactions and operating niche pharma products internationally. Immedica has capabilities to provide optimal access of specialty care medicines to patients with significant medical needs, including key areas such as regulatory affairs, pharmacovigilance, medical affairs, pricing & reimbursement, quality and product distribution.
Immedica’s main owner is Impilo AB, a private Nordic investment company established in 2017, with more than SEK 3.6 billion in committed capital from leading Nordic and international investors.
For more information
Håkan Garpenstrand, Head of Business Development
Telephone: +46 (0)70 880 29 32